Antipodes Partners’s Medtronic MDT Stock Holding History

Antipodes Partners’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-730	Closed	-$70.1K	–	143
2025 Q4	$70.1K	Buy	+730	New	+$70.9K	﹤0.01%	98
2025 Q2	–	Sell	-1,007	Closed	-$90.5K	–	117
2025 Q1	$90.5K	Buy	+1,007	New	+$90.1K	﹤0.01%	75
2022 Q1	–	Sell	-1,095,099	Closed	-$113M	–	39
2021 Q4	$113M	Buy	1,095,099 +84,271	+8%	+$9.76M	4.07%	10
2021 Q3	$127M	Sell	1,010,828 -36,160	-3%	-$4.68M	4.33%	8
2021 Q2	$130M	Sell	1,046,988 -191,530	-15%	-$24M	4.69%	9
2021 Q1	$146M	Sell	1,238,518 -5,320	-0.4%	-$624K	5.93%	4
2020 Q4	$146M	Buy	1,243,838 +322,345	+35%	+$35.5M	6.33%	4
2020 Q3	$95.8M	Buy	921,493 +161,688	+21%	+$16.2M	4.39%	8
2020 Q2	$69.7M	Buy	759,805 +19,918	+3%	+$1.91M	3.15%	11
2020 Q1	$66.7M	Buy	739,887 +134,412	+22%	+$14.3M	3.49%	15
2019 Q4	$68.7M	Sell	605,475 -18,893	-3%	-$2.07M	3.09%	12
2019 Q3	$67.8M	Buy	624,368 +414,448	+197%	+$43.2M	3.24%	15
2019 Q2	$20.4M	Buy	+209,920	New	+$19.2M	0.94%	22

Other funds holding MDT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Antipodes Partners's MDT Position: Q1 2026 in Review

Antipodes Partners sold out of Medtronic (MDT) in Q1 2026, closing a stake of 730 shares — an estimated $70.1K sold.

Antipodes Partners first reported a position in MDT in Q2 2019 and held it in 13 quarters. The position peaked at $146M in Q1 2021. 2,231 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

Antipodes Partners reported no remaining Medtronic position as of Q1 2026 after selling out during the quarter.
Antipodes Partners sold 730 Medtronic shares in Q1 2026, an estimated $70.1K.
Antipodes Partners first reported a position in Medtronic in Q2 2019 and held it in 13 quarters.
Antipodes Partners's Medtronic position peaked at $146M in Q1 2021.
2,231 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.